Effects Of the Gastric Bypass ALTERNATIVE ® Regimen On Type 1 Diabetes Active Ingredients

Abstract

The Gastric Bypass ALTERNATIVE® (a.k.a GBA) regimen is an innovative non-surgical weight reduction regimen with 80,000 users experience in 8 years. The results to date show that successful users are reporting weight reduction at a rate of 2 to 4 times that of bariatric surgery patients.

The regimen is made of:
> A unique, sophisticated weight analysis to reflect the causes of obesity for each individual
> A custom prepared Anti-Cravings, Gastric Bypass EFFECT, reinforcement pills, stress & sleep pills, night pills
> A strict boot camp (Facebook.com/groups/LOST100) with 22,000 people managed by Don Karl Juravin
> Medical oversight by Dr. Marcus K. Free

Full text

v1.1
Mostcomprehensiveresearchstudyon:
EffectsOftheGastricBypass
ALTERNATIVE
®
RegimenOnType1
Diabetes
Authors:RouzbehMotieiLangroudiMD,DonKarl
Juravin(inventor),andMarcusK.FreeMD
Abstract
The Gastric Bypass ALTERNATIVE
®(a.k.a GBA) regimen is an innovative nonsurgical weight           
reduction regimen with 80,000 users experience in 8 years. The results to date show that              
successful users are reporting weight reduction at a rate of 2 to 4 times that of bariatric                
surgerypatients.Theregimenismadeof:
1. Aunique,sophisticatedweightanalysistoreflectthecausesofobesityforeachindividual
2. A custom prepared AntiCravings, Gastric Bypass EFFECT, reinforcement pills, stress &          
sleeppills,nightpills 
3. A strict boot camp (Facebook.com/groups/LOST100) with 22,000 people managed by Don          
KarlJuravin
4. MedicaloversightbyDr.MarcusK.Free
Study
This research paper discusses the effects of the components of the Gastric Bypass            
ALTERNATIVE
®
regimenondiabetes,insulinrelease,andweightloss.
ActiveIngredients
The active ingredients in the Gastric Bypass ALTERNATIVE (a.k.a GBA) regimen are: Beta            
Glucan, Camellia Sinensis, Chromium, Fibersol, Green Coffee Bean Extract, Guar Gum,          

v1.1
Higenamine Hydrochloric Acid, Inulin, Konjac, Magnesium Stearate, Naringin, Raspberry        
Ketones, Silicon Dioxide, Theobromine, Vitamin B6, Vitamin B12, Vitamin D, Willow, Xanthan,           
and Yohimbine. Here, we review the existing research articles regarding the effects of each             
ingredientontype1orinsulindependentdiabetes.
BetaGlucan
Beta glucan decreases blood glucose without inducing hypoglycemia in type 1          
diabetics.
● Beta glucan consumption before bedtime decreases blood glucose during early night          
hoursintype1diabeticchildrenwithoutinducingnocturnalhypoglycemia(Rami2001).
● Beta glucan protects against type 1 diabetes in mice through induction of innate immune             
response and modulation of T cell response to pancreatic beta cells (KarumuthilMelethil           
2014,Kida1992).
Chromium
Chromium blood level is lower in type 1 diabetics, especially in patients with poor             
glycemic control, while chromium intake (200 microg 3 times daily) improves          
outcome.
● Chromium is involved in insulin signal transduction, insulin and glucose metabolism and           
cellularantioxidativedefense(Lin2015,Anderson2000).
● Chromium blood level is lower in type 1 diabetics, especially in patients with poor glycemic              
control(Gluschenko2016,Lin2015,Karagun2012).
● Suboptimal chromium intake increases the risk of diabetes as chromium intake improves           
glucoseintoleranceintype1diabetes(Anderson2000).
● Chromium picolinate (200 microg 3 times daily for 3 months) decreases HbA1c in type 1              
diabetes(Fox1998).
● Chromium (200μg) increases insulin sensitivity in individuals with type 1 diabetes and also            
permitsreductionsindosagesofinsulinafterjust10days(Chen1997).

v1.1
GuarGum
Guar gum (30 g daily) decreases fasting and postprandial blood glucose (by           
19%), hemoglobin A1c (HbA1c, by 0.8) and lowdensitylipoprotein (LDL)        
cholesterol(by20%)intype1diabetics.
● Guar gum (4 times per day for 6 weeks) decreases fasting blood glucose, hemoglobin A1c              
(HbA1c) and lowdensitylipoprotein (LDL) cholesterol (by 20%) in type 1 diabetics, shown           
inarandomizeddoubleblindstudy(VuorinenMarkkola1992).
● Guar gum (4 times per day for 4 weeks) decreases blood glucose levels after breakfast              
and lunch, daily insulin requirements and serum total cholesterol (by 21%) in type 1             
diabetics,showninarandomizeddoubleblindstudy(Ebeling1988).
● Guar gum (29 g daily for 1 month) decreases postprandial blood glucose (by 19%) and              
HbA1(by0.8)intype1diabetics(Vaaler1986).
● Guar gum (5% of daily carbohydrate intake to a maximum of 30 g daily for 3 weeks)                
decreases HbA1c, glucosuria and serum total cholesterol in type 1 diabetic children           
(Paganus1987).
Naringin
Animal studies show that Naringin does not reduce blood glucose levels in type            
1 diabetics, but improves atherogenesis and is helpful in preventing diabetic          
ketoacidosis.
● Naringin ameliorates cardiac hypertrophy in type 1 diabetic mice by inhibiting oxidative           
stress(Adebiyi2016).
● Naringin improves plasma insulin, hepatic glycogen content, blood acidity and ketone          
bodies but not fasting blood glucose in type 1 diabetic mice. In other words, although              
Naringin is not hypoglycemic, it ameliorates ketoacidosis and complications of diabetic          
ketoacidosis(Murunga2016).
● Naringin is not hypoglycemic in type 1 diabetic rats, but it improves atherogenic index as it               
decreases total cholesterol and triglycerides and increases highdensity lipoproteins (HDL)         

v1.1
(Xulu2012).
VitaminB6
Vitamin B6 metabolism is altered in type 1 diabetes and its deficiency may            
contribute to type I diabetes onset. Conversely, vitamin B6 (100mg daily)          
normalizesendothelialdysfunctionintype1diabetes.
● Vitamin B6 deficiency results in deficient formation of derivatives (like pyridoxal          
5'phosphate) necessary for pancreatic islet function and the lack of the derivative may            
contribute to the appearance of pancreatic islet autoimmunity and type I diabetes onset            
(Rubi2012).
● Vitamin B6 (100mg daily) normalize endothelial dysfunction in type 1 diabetic children, with            
theeffectmaintainingover8weeks(MacKenzie2006).
● Vitamin B6 metabolism is altered in type 1 diabetes, resulting in its deficiency and diabetic              
complications(Masse2012,Kodentsova1994).
VitaminB12
Some type 1 diabetic patients will develop Vitamin B12 deficiency anemia,          
obligatingVitaminB12supplementation.
● As type 1 diabetes is an autoimmune disease, there is an increased risk of other              
autoimmune disorders including pernicious anemia, a type of Vitamin B12deficient anemia          
needing lifelong supplementation with Vitamin B12 (De Block 2008, Perros 2000, Davis           
1992).
VitaminD
Vitamin D (500 to 4000 IU daily) decreases type 1 diabetes risk by regulating             
immunesystemandcalciumhomeostasisanditsdirecteffectonbetacells.
● Vitamin D deficiency increases the incidence of type 1 diabetes. Conversely, early and            
longterm vitamin D supplementation decreases diabetes risk by regulating immune         
system and calcium homeostasis and its direct effect on beta cells that renders them more              

v1.1
resistant to cellular stress (Griz 2014, Badenhoop 2012, WoldenKirk 2011, Hypponen          
2010,Luong2005,Mathieu2005a,Mathieu2005b).
● High dose Vitamin D (50 microg or 2000 IU daily) but not low dose (10 microg or 400 IU                  
daily)haveastrongprotectiveeffectontype1diabetes(Harris2005,Harris2002).
● Vitamin D supplementation during early life (infancy) decreases type 1 diabetes risk during            
laterlifeby29%(Dong2013,Zipitis2008).
● Below normal vitamin D levels are observed in 71% of type 1 diabetic individuals.             
Moreover, insulin requirement is higher in type 1 diabetics with decreased serum vitamin D             
levels(Thnc2011,Holick2005).
● Higher vitamin D levels are associated with lower HbA1c levels in type 1 diabetics (Al              
Sawah2016).
● Vitamin D supplementation (4000 IU daily) improves HbA1c after 12 weeks in vitamin            
Ddeficienttype1diabetics(Aljabri2010).
● Vitamin D deficiency predisposes to type 1 diabetes, while Vitamin D supplementation (500            
IUto1000IUdaily)preventthedisease(Mathieu2015).
● Vitamin D supplementation influences immune regulation and subsequently may prevent         
progressiontotype1diabetesingeneticallysusceptibleindividuals(Harinarayan2014).
References
1. Adebiyi,A.,Adebiyi,O.,Owira,P.(2016).NaringinMitigatesCardiacHypertrophybyReducingOxidative
StressandInactivatingcJunNuclearKinase1ProteininTypeIDiabetes.JournalofCardiovascular
Pharmacology[online],67(2),pp.13644.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/26421421
[Accessed06.01.2017].
2. Aljabri,K.,Bokhari,S.,Khan,M.(2010).GlycemicchangesaftervitaminDsupplementationinpatientswith
type1diabetesmellitusandvitaminDdeficiency.AnnalsofSaudiMedicine[online],30(6),pp.4548.
Availablefrom:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994161/[Accessed04.01.2017].
3. AlSawah,S.,Compher,C.,Hanlon,A.,etal.(2016).25HydroxyvitaminDandglycemiccontrol:A
crosssectionalstudyofchildrenandadolescentswithtype1diabetes.DiabetesResearchandClinical
Practice[online],115,pp.549.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/27242123[Accessed
05.01.2017].
4. Anderson,R.(2000).Chromiuminthepreventionandcontrolofdiabetes.DiabetesandMetabolism[online],
26(1),pp.227.Availablefrom:http://www.emconsulte.com/article/79857/alertePM[Accessed28.12.2016].
5. Badenhoop,K.,Kahles,H.,PennaMartinez,M.(2012).VitaminD,immunetolerance,andpreventionoftype
1diabetes.CurrentDiabetesReports[online],12(6),pp.63542.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/22976537[Accessed05.01.2017].

v1.1
6. Chen,S.,Sun,Y.,Chen,X.(1997).Effectofjiangtangkangonbloodglucose,sensitivityofinsulinandblood
viscosityinnoninsulindependentdiabetesmellitus[inChinese].ZhongguoZhongXiYiJieHeZaZhi,17,
pp.666–8.Availablefrom:http://www.ncbi.nlm.nih.gov/pubmed/10322847[Accessed02.06.2016].
7. Davis,R.,McCann,V.,Stanton,K.(1992).Type1diabetesandlatentperniciousanaemia.TheMedical
JournalofAustralia[online],156(3),pp.1602.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/1545717[Accessed28.12.2016].
8. DeBlock,C.,DeLeeuw,I.,VanGaal,L.(2008).Autoimmunegastritisintype1diabetes:aclinicallyoriented
review.JournalofClinicalEndocrinologyandMetabolism[online],93(2),pp.36371.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/18029461[Accessed28.12.2016].
9. Dong,J.,Zhang,W.,Chen,J.,etal.(2013).VitaminDintakeandriskoftype1diabetes:ametaanalysisof
observationalstudies.Nutrients[online],5(9),pp.355162.Availablefrom:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798920/[Accessed05.01.2017].
10. Ebeling,P.,YkiJärvinen,H.,Aro,A.,etal.(1988).Glucoseandlipidmetabolismandinsulinsensitivityin
type1diabetes:theeffectofguargum.AmericanJournalofClinicalNutrition[online],48(1),pp.98103.
Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/3291601[Accessed27.12.2016].
11. Fox,G.,Sabovic,Z.(1998).Chromiumpicolinatesupplementationfordiabetesmellitus.TheJournalof
FamilyPractice[online],46(1),pp.836.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/9451374
[Accessed28.12.2016].
12. Gluschenko,N.,Vasylyshyn,K.,Roschupkin,A.,etal.(2016).Thecontentofmicroelementsinbloodserum
anderythrocytesinchildrenwithdiabetesmellitustypeIdependingonlevelofglycemiccontrol.Georgian
MedNews[online],250,pp.6671.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/26870978
[Accessed28.12.2016].
13. Griz,L.,Bandeira,F.,Gabbay,M.,etal.(2014).VitaminDanddiabetesmellitus:anupdate2013.Arquivos
BrasileirosdeEndocrinologiaeMetabologia[online],58(1),pp.18.Availablefrom:
http://www.scielo.br/pdf/abem/v58n1/00042730abem5810001.pdf[Accessed05.01.2017].
14. Harinarayan,C.(2014).VitaminDanddiabetesmellitus.Hormones[online],13(2),pp.16381.Available
from:http://www.hormones.gr/8472/article/article.html[Accessed04.01.2017].
15. Harris,S.(2005).VitaminDintype1diabetesprevention.JournalofNutrition[online],135(2),pp.3235.
Availablefrom:http://jn.nutrition.org/content/135/2/323.long[Accessed05.01.2017].
16. Harris,S.(2002).CanvitaminDsupplementationininfancypreventtype1diabetes?NutritionReviews
[online],60(4),pp.11821.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/12002683[Accessed
05.01.2017].
17. Holick,M.(2005).VitaminD:importantforpreventionofosteoporosis,cardiovascularheartdisease,type1
diabetes,autoimmunediseases,andsomecancers.SouthernMedicalJournal[online],98(10),pp.10247.
Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/16295817[Accessed05.01.2017].
18. Hyppönen,E.(2010).VitaminDandincreasingincidenceoftype1diabetesevidenceforanassociation?
DiabetesObesityandMetabolism[online],12(9),pp.73743.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/20649624[Accessed05.01.2017].
19. Karagun,B.,Temiz,F.,Ozer,G.,etal.(2012).Chromiumlevelsinhealthyandnewlydiagnosedtype1
diabeticchildren.PediatricsInternational[online],54(6),pp.7805.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/22783884[Accessed28.12.2016].
20. KarumuthilMelethil,S.,Gudi,R.,Johnson,B.,etal.(2014).Fungalβglucan,aDectin1ligand,promotes

v1.1
protectionfromtype1diabetesbyinducingregulatoryinnateimmuneresponse.JournalofImmunology
[online],193(7),pp.330821.Availablefrom:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170060/
[Accessed27.12.2016].
21. Kida,K.,Inoue,T.,Kaino,Y.,etal.(1992).Animmunopotentiatorofbeta1,6;1,3Dglucanpreventsdiabetes
andinsulitisinBBrats.DiabetesResearchandClinicalPractice[online],17(2),pp.759.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/1425150[Accessed28.12.2016].
22. Kodentsova,V.,Vrzhesinskaia,O.,Sokol'nikov,A.,etal.(1994).Vitaminmetabolisminchildrenwith
insulindependentdiabetesmellitus.Effectoflengthofillness,severity,anddegreeofdisruptionofsubstance
metabolism.VoprosyMeditsinskoiKhimii[online],40(4),pp.338.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/7975378[Accessed04.01.2017].
23. Lin,C.,Huang,Y.(2015).Chromium,zincandmagnesiumstatusintype1diabetes.CurrentOpinionin
ClinicalNutritionandMetabolicCare[online],18(6),pp.58892.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/26406393[Accessed28.12.2016].
24. Luong,K.,Nguyen,L.,Nguyen,D.(2005).TheroleofvitaminDinprotectingtype1diabetesmellitus.
DiabetesMetabolismResearchandReviews[online],21(4),pp.33846.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/15852446[Accessed05.01.2017].
25. MacKenzie,K.,Wiltshire,E.,Gent,R.,etal.(2006).FolateandvitaminB6rapidlynormalizeendothelial
dysfunctioninchildrenwithtype1diabetesmellitus.Pediatrics[online],118(1),pp.24253.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/16818571[Accessed29.12.2016].
26. Massé,P.,Boudreau,J.,Tranchant,C.,etal.(2012).Type1diabetesimpairsvitaminB(6)metabolismatan
earlystageofwomen'sadulthood.AppliedPhysiologyNutritionandMetabolism[online],37(1),pp.16775.
Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/22288928[Accessed29.12.2016].
27. Mathieu,C.(2015).VitaminDanddiabetes:Wheredowestand?DiabetesResearchandClinicalPractice
[online],108(2),pp.2019.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/25700626[Accessed
04.01.2017].
28. Mathieu,C.,Badenhoop,K.(2005a).VitaminDandtype1diabetesmellitus:stateoftheart.Trendsin
EndocrinologyandMetabolism[online],16(6),pp.2616.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/15996876[Accessed05.01.2017].
29. Mathieu,C.,Gysemans,C.,Giulietti,A.,etal.(2005b).VitaminDanddiabetes.Diabetologia[online],48(7),
pp.124757.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/15971062[Accessed05.01.2017).
30. Murunga,A.,Miruka,D.,Driver,C.,etal.(2016).GrapefruitDerivedFlavonoidNaringinImproves
KetoacidosisandLipidPeroxidationinType1DiabetesRatModel.PLoSOne[online],11(4),pp.e0153241.
Availablefrom:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830547/[Accessed06.01.2017].
31. Paganus,A.,Mäenpää,J.,Akerblom,H.,etal.(1987).Beneficialeffectsofpalatableguarandguarplus
fructosedietsindiabeticchildren.ActaPaediatricaScandinavica[online],76(1),pp.7681.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/3551494[Accessed27.12.2016].
32. Perros,P.,Singh,R.,Ludlam,C.,etal.(2000).PrevalenceofperniciousanaemiainpatientswithType1
diabetesmellitusandautoimmunethyroiddisease.DiabeticMedicine[online],17(10),pp.74951.Available
from:https://www.ncbi.nlm.nih.gov/pubmed/11110510[Accessed28.12.2016].
33. Rami,B.,Zidek,T.,Schober,E.(2001).Influenceofabetaglucanenrichedbedtimesnackonnocturnal
bloodglucoselevelsindiabeticchildren.JournalofPediatricGastroenterologyandNutrition[online],32(1),
pp.346.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/11176321[Accessed27.12.2016].

v1.1
34. Rubí,B.(2012).Pyridoxal5'phosphate(PLP)deficiencymightcontributetotheonsetoftypeIdiabetes.
MedicalHypotheses[online],78(1),pp.17982.https://www.ncbi.nlm.nih.gov/pubmed/22088923[Accessed
29.12.2016].
35. Thnc,O.,Cetinkaya,S.,Kizilgün,M.,etal.(2011).VitaminDstatusandinsulinrequirementsinchildrenand
adolescentwithtype1diabetes.JournalofPediatricEndocrinologyandMetabolism[online],24(1112),pp.
103741.Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/22308861[Accessed05.01.2017].
36. Vaaler,S.,Hanssen,K.,DahlJørgensen,K.,etal.(1986).Diabeticcontrolisimprovedbyguargumand
wheatbransupplementation.DiabeticMedicine[online],3(3),pp.2303.Availablefrom:
https://www.ncbi.nlm.nih.gov/pubmed/3030619[Accessed27.12.2016].
37. VuorinenMarkkola,H.,Sinisalo,M.,Koivisto,V.(1992).Guargumininsulindependentdiabetes:effectson
glycemiccontrolandserumlipoproteins.AmericanJournalofClinicalNutrition[online],56(6),pp.105660.
Availablefrom:https://www.ncbi.nlm.nih.gov/pubmed/1442657[Accessed27.12.2016].
38. WoldenKirk,H.,Overbergh,L.,Christesen,H.,etal.(2011).VitaminDanddiabetes:itsimportanceforbeta
cellandimmunefunction.MolecularandCellularEndocrinology[online],347(12),pp.10620.Available
from:https://www.ncbi.nlm.nih.gov/pubmed/21889571[Accessed05.01.2017].
39. Xulu,S.,OromaOwira,P.(2012).Naringinamelioratesatherogenicdyslipidemiabutnothyperglycemiain
ratswithtype1diabetes.JournalofCardiovascularPharmacology[online],59(2),pp.13341.Available
from:https://www.ncbi.nlm.nih.gov/pubmed/21964158[Accessed06.01.2017].
40. Zipitis,C.,Akobeng,A.(2008).VitaminDsupplementationinearlychildhoodandriskoftype1diabetes:a
systematicreviewandmetaanalysis.ArchivesofDiseaseinChildhood[online],93(6),pp.5127.Available
from:http://adc.bmj.com/content/93/6/512.full.pdf+html[Accessed05.01.2017].
Footnote
ThisresearchwassponsoredbyMustCureObesityCO.(Florida2000)
DonKarlJuravinistheinventor
